Yahoo Finance

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca's ENHERTU in combination with pertuzumab significantly improved progression-free survival versus current ...
Nasdaq

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a ...
Yahoo Finance

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to ...
Cure Today

Presurgical Enhertu Combo Elicits Response Benefit in HER2+ Early Breast Cancer

Enhertu plus THP improved pCR rates in HER2-positive early breast cancer compared to ddAC-THP, with notable benefits in hormone receptor-positive and negative populations. The DESTINY-Breast11 trial ...